Literature DB >> 3474300

Prevalence, clinical significance, and strain specificity of neutralizing antibody to the human immunodeficiency virus.

A M Prince, D Pascual, L B Kosolapov, D Kurokawa, L Baker, P Rubinstein.   

Abstract

A semiautomated microtiter assay has been developed to quantitate neutralizing antibody to the human immunodeficiency virus. This assay has been found to be highly specific. Forty-four sera that were negative by enzyme-linked immunosorbent assay (ELISA) were tested under code: 42 were negative (less than 1:2), and 2 had titers of 1:2. By contrast, of 178 sera positive by western blot, 92.7% had detectable neutralizing antibody, and 12.5% had titers greater than or equal to 1:128. Neutralizing antibody titers correlated poorly with clinical diagnosis and T4/T8 ratios. Different isolates differed quantitatively in their sensitivity to neutralization by antibodies obtained from different patients; however, all strains tested so far have been neutralizable by all the sera tested. Neutralizing antibody titers correlated weakly, if at all, with direct or competition ELISA titers.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3474300     DOI: 10.1093/infdis/156.2.268

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.

Authors:  R Q Warren; S A Anderson; W M Nkya; J F Shao; C W Hendrix; G P Melcher; R R Redfield; R C Kennedy
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

Review 2.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

3.  Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping.

Authors:  L D Papsidero; M Sheu; F W Ruscetti
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

4.  Application of a rapid microplaque assay for determination of human immunodeficiency virus neutralizing antibody titers.

Authors:  C V Hanson; L Crawford-Miksza; H W Sheppard
Journal:  J Clin Microbiol       Date:  1990-09       Impact factor: 5.948

5.  Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers.

Authors:  P Rossi; V Moschese; P A Broliden; C Fundaró; I Quinti; A Plebani; C Giaquinto; P A Tovo; K Ljunggren; J Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

6.  Priming of CD4+ T cells specific for conserved regions of human immunodeficiency virus glycoprotein gp120 in humans immunized with a recombinant envelope protein.

Authors:  S Abrignani; D Montagna; M Jeannet; J Wintsch; N L Haigwood; J R Shuster; K S Steimer; A Cruchaud; T Staehelin
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

7.  B- and T-lymphocyte responses to an immunodominant epitope of human immunodeficiency virus.

Authors:  R D Schrier; J W Gnann; A J Langlois; K Shriver; J A Nelson; M B Oldstone
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

8.  Agreement study between two laboratories of immunofluorescence as a confirmatory test for human immunodeficiency virus type 1 antibody screening.

Authors:  J Mahony; K Rosenthal; M Chernesky; S Castriciano; E Scheid; M Blajchman; D Harnish
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

9.  Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.

Authors:  L S Sawyer; M T Wrin; L Crawford-Miksza; B Potts; Y Wu; P A Weber; R D Alfonso; C V Hanson
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV.

Authors:  A M Prince; B Horowitz; L Baker; R W Shulman; H Ralph; J Valinsky; A Cundell; B Brotman; W Boehle; F Rey
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.